4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-024249
CHIEF FINANCIAL OFFICER sold 6,250 shares at an average $24.61 ($153,829)
- CHIEF FINANCIAL OFFICER acquired 6,250 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-09-27 | Option exercise 10b5-1 | +4,250 | $2.48 | $10,540 | 4,250 | D |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-09-27 | Sale 10b5-1 | −4,250 | $24.27 | $103,161 | 0 | D |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-09-30 | Option exercise 10b5-1 | +2,000 | $2.48 | $4,960 | 2,000 | D |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-09-30 | Sale 10b5-1 | −2,000 | $25.33 | $50,668 | 0 | D |
| Derivatives | |||||||
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-09-27 | Option exercise · Stock Option (right to buy) 10b5-1 | −4,250 | 194,879 | D | ||
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-09-30 | Option exercise · Stock Option (right to buy) 10b5-1 | −2,000 | 192,879 | D | ||
| Open-market sales · 6,250 sh · avg $24.61 · $153,829 | |||||||
Loading xslF345X05/form4-10012024_111017.xml…